Dr. Scott Tagawa Discusses IMMU-132 in Patients With Urothelial Carcinoma

Video

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.

Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer.

IMMU-132 is an anti—TROP-2 antibody-drug conjugate comprised of SN-38. Regarding safety, the agent is not as toxic compared with other antibody-drug conjugates, Tagawa explains. In a phase I/II study, grade 3 neutropenia was observed in patients who received IMMU-132, but grade 1/2 diarrhea was one of the most common adverse events.

Preliminary findings demonstrate a median progression-free survival of 8.1 months with 50% maturity, and a median overall survival of 10.8 months, with 79% of patients still alive.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD